QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, Masuishi T, Yasui H, Kagawa Y, Komatsu Y, Oki E, Yamamoto Y, Kawakami H, Misumi T, Taniguchi H, Yamazaki K, Muro K, Yoshino T, Kato T, Tsuji A.
Bando H, et al. Among authors: yamamoto y.
Med. 2024 Jun 14:S2666-6340(24)00216-2. doi: 10.1016/j.medj.2024.05.012. Online ahead of print.
Med. 2024.
PMID: 38901425